INHIBITION OF C-MYC TO TREAT POLYCYSTIC KIDNEY DISEASE

提出了开发治疗多囊肾病（PKD）的药物疗法。PKD是最常见的人类遗传性疾病，在美国影响约50万人。 原癌基因c-myc的过表达已被证明是啮齿动物PKD模型（模拟人类疾病）中囊肿发育的组成部分。 我们提出了一个假设，即使用与c-myc mRNA AUG翻译起始位点（AVI-4126）互补的磷酸二酰胺吗啉代寡核苷酸（PMO）抑制c-myc表达将停止或减缓PKD的进展。 该化合物目前正处于临床前开发阶段，用于治疗成骨肉瘤和再狭窄。使用AVI-4126治疗PKD是一种新的方法，目前还没有有效的药物治疗基础疾病。 AVI-4126在人类疾病小鼠模型中的初步结果表明安全性和有效性。我们提出的研究概述了以下四个目标：1）评估PMO获得肾囊肿上皮细胞的适当细胞的能力，2）。在C57 BL/6 J-cpk小鼠中评估反义PM 0对c-myc的抑制，和3.）在Balb-c-cpk小鼠中评估反义PMO对c-myc的抑制4.）Han：SPRD大鼠中反义PMO对c-myc抑制的评价。 这项研究如果成功，将导致第二阶段资金的建议，将AVI-4126的使用带入药物市场。拟议的商业应用：本提案中概述的研究旨在检测目前正在PKD模型中评估的用于再狭窄和成骨肉瘤的化合物。 该提案的目的是测试将AVI-4126或其他反义化合物引入药物市场的可行性，并为PKD治疗的侵入性姑息手术提供廉价的替代方案。I期的疗效证据将导致II期临床前开发的提议。

Development of a drug therapy to treat polycystic kidney disease (PKD) is proposed. PKD is the most common human genetic disease affecting approximately one half million people in the USA. The over-expression of the proto-oncogene c-myc has been shown to be integral to cyst development in rodent PKD models which mimic the human disease. We propose the hypothesis that inhibition of c-myc expression using phosphorodiamidate morpholino oligonucleotides (PMOs) complementary to c-myc mRNA AUG translation start site (AVI-4126) will stop or slow progression of PKD. This compound is currently in preclinical development for use in the treatment of osteogenic sarcoma and restinosis. The use of AVI-4126 in the treatment of PKD is a novel approach to a disease for which there are currently no effective drugs for treatment of the underlying disease. Preliminary results with AVI-4126 in a mouse model of human disease suggests both safety and efficacy. We propose studies outlined by the following four aims: l) Evaluate the ability of PMOs to gain access to the appropriate cells of the renal cyst epithelium, 2.) Evaluation of inhibition of c-myc by antisense PMOs in C57BL/6J-cpk mice, and 3.) Evaluation of inhibition of c-myc by antisense PMOs in Balb-c-cpk mice 4.) Evaluation of inhibition of c-myc by antisense PMOs in Han:SPRD rats. The proposed research, if successful, would lead to a proposal for Phase II funding to bring the use of AVI-4126 into the drug market. PROPOSED COMMERCIAL APPLICATIONS: The studies outlined in this proposal are designed to test a compound currently being evaluated for restinosis and osteogenic sarcoma in a model of PKD. The intent of this proposal is to test the feasibility of bringing AVI-4126 or other antisense compounds into the drug market and provide an inexpensive alternative to invasive palliative procedures for PKD treatment. Evidence of efficacy in Phase I will lead to a proposal for preclinical development in Phase Il.